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The active metabolite of leflunomide, A77 1726 inhibits the proliferation of a variety of mammalian cell lines in culture. Epidermal growth factor 
(EGF)-dependent proliferation is inhibited by A77 1726 at an effective dose of 30-40 ,uM. A77 1726 appears to directly inhibit the EGF receptor 
tyrosine-specific kinase activity both in intact ceils and purified EGF receptors at the same effective dose. These data suggest that leflunomide 
inhibits cellular proliferation by the inhibition of tyrosine-specific kinase activities. 
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1. INTRODUCTION 
A variety of cell surface receptors, uch as the epider- 
mal growth factor (EGF) receptor, posses a ligand-sen- 
sitive intrinsic tyrosine-specific kinase activity [1,2]. Li- 
gand binding to one of these receptors leads to tyrosine 
phosphorylation of intracellular substrates and are 
thought o be one of the intracellular signals necessary 
for DNA synthesis and cell division. Several aborato- 
ries are investigating tyrosine-specific protein kinase in- 
hibitors as an approach to cell growth inhibition. A 
variety of compounds from natural origins, such as fla- 
vonoids [3] or erbstatin [4], as well as synthetic om- 
pounds [5,6], have been reported to inhibit tyrosine ki- 
nase activity. Thus, specific inhibitors of tyrosine ki- 
nases are of great interest as therapeutic agents and 
pharmacologic tools to study tyrosine phosphorylation 
and its role in cell growth control. 
Leflunomide, a novel immunomodulatory drug, has 
been shown to be effective in the treatment of several 
autoimmune animal diseases with minimal toxicity 
[7,8]. The in vitro investigations concerning its mode of 
action demonstrated that leflunomide mediates its ef- 
fects, at least in part, by inhibition of cellular prolifera- 
tion of a wide variety of cultured cell lines [8]. These 
data suggested that leflunomide might interfere with a 
common mechanism leading to cell division. The impor- 
tance of tyrosine kinases in the regulation of cell prolif- 
eration and the structure of leflunomide l d us to exam- 
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ine its ability to inhibit tyrosine-specific protein kinase 
activity of growth factor receptors. 
2. MATERIALS AND METHODS 
The active metabolite of leflunomide, A77 1726, was supplied by 
Hoechst, AG, Weisbaden, Germany. Prior to use it was dissolved 
directly into the buffer and used without further purification. 
2.1. Cell culture 
The human foreskin fibroblast (HFF) and squamous cell carcinoma 
(KB or A431) cell lines used for these experiments were cultured in 
Dulbecco's modified Eagle's medium (DMEM) (Sigma) supplemented 
with 10% iron-supplemented calf serum. Murine splenic T- and B- 
cells, a cytotoxic T-cell line (CTLL), and B-cell lines (A20-2-J or 7D4) 
were maintained in RPMI 1640 medium (Sigma) supplemented with 
10% fetal calf serum. All cultures were maintained at 37°C in an 
humidified atmosphere with 5% CO2. Cellular proliferation was meas- 
ured by the incorporation of thymidine into DNA after a 24 h pulse 
with [3H]TdR (1 ktCi/well; ICN Radiochemicals) [9]. The results are 
expressed as the mean of four replicate cultures. The maximum stand- 
ard deviation (S.D.) for each point was <- 15%. 
2.2. Phosphorylation f the EGF receptor inintact cells 
Phosphorylation f the EGF receptor in intact cells was determined 
with an anti-phosphotyrosine antibody as previously described [10] 
and outlined below. Human foreskin fibroblast cells (3 × 105) were 
seeded in 25 cm 2 flasks in serum-free medium supplemented with 20 
ng/ml EGF (UBI) and with or without A77 1726. The cells were 
cultured for 3 days and then transferred toserum-free medium supple- 
mented with A77 1726 alone for an additional 24 h. The EGF receptor 
was stimulated with 100 ng EGF per flask for 10 rain at 37°C. After 
washing 2× with ice-cold phosphate buffered saline (PBS), the mono- 
layer was solubilized with buffer containing 1% Triton-X-100, 10% 
glycerol, 20 mM N-2-hydroxyethylpiperazine-N'-2-ethane sulfonic 
acid (HEPES), pH 7.4, 1 mM EGTA, 10 mM iodoacetic acid and 100 
ktM phenylmethylsulfonyl fluoride (PMSF), for 10 rain. 
After determination f the protein concentration for the lysates, 50 
~g of loaded soluble protein was resolved by SDS-PAGE and then 
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transferred electrophoretically to nitrocellulose sheets. Phosphoty- 
rosine-containing proteins were identified with an anti-phosphoty- 
rosine monoclonal ntibody (PY-20, ICN Immunochemicals) and de- 
tected by sequential blotting with biotinylated goat anti-mouse IgG, 
streptavidin alkaline phosphatase conjugate and 5-bromo-4-chloro-3- 
indolyphosphate p-toluidine salt/nitroble t trazolium chloride (BCIP/ 
NBT) (Bethesda Research Labs). 
2.3. Determination of the EGF receptor kinase activity 
The tyrosine-specific protein kinase activity of the EGF receptor 
was determined asdescribed previously using a synthetic peptide sub- 
strate [11]. For these determinations, the EGF receptor was purified 
from A431 cells by affinity chromatography on immobilized wheat 
germ agglutanin as previously described [12]. The EGF receptor was 
specifically eluted with 3 mM N-acetyl glucosamine and dialized prior 
to use. The kinase reaction was carried out in a total volume of 50/tl 
in a buffer containing 20 mM HEPES, pH 7.4, 100 mM NaC1, 2 mM 
MgCI 2 and 100,uM sodium orthovanadate. Purified EGF receptor (15 
/11) was preincubated with or without 50 ng EGF and A77 1726 for 
20 min to initiate the kinase assay. The kinase reaction was started by 
the addition of [y32p]ATP at 4°C for 5 min to allow for auto- 
phosphorylation. The synthetic peptide substrate (RR-src) (Peninsula 
Labs) was then added and the reaction allowed to proceed for an 
additional 10 min at 4°C. The reaction was stopped by the addition 
of 50 ,ul ice-cold 10% trichloroacetic a id. Following centrifugation, 
the supernatant containing the phosphorylated RR-src peptide was 
transferred onto phosphocellulose paper (Whatman P81) and washed 
three times in 75 mM phosphoric acid. The dried papers were then 
counted with a liquid scintilation counter. The results are expressed 
as the mean of three seperate experiments for each data point. 
2.4. Determination of protein kinase C activity 
Protein kinase C activity was measured using the PKC Assay Sys- 
tem purchased from Gibco BRL, and all proceedures were performed 
as per the manufacture's in tructions. This assay system is based on 
the proceedure previously described by Yasuda et al. [13]. The PKC 
used for these determinations was purified from HL-60 cells by DEAE 
chromatography. Kinase activity was determined by incorporation of
32p from [~'32p]ATP (3,000,uCi/pmol) into a synthetic peptide substrate 
derived from myelin basic protein (provided with the assay kit). The 
specificity of the assay for PKC was confirmed by using the PKC 
pseudosubstrate inhibitor peptide, PKC (19 36) [13]. 
3. RESULTS 
3.1. Inhibition of EGF-dependent proliferation by A77 
1726 
It was previously demonstrated that A77 1726 (Fig. 
1) inhibits the proliferation of a wide variety of cell lines 
[8]. The ability of A77 1726 to inhibit the serum-depend- 
ent proliferation of leukocytes and tumor cell lines is 
summarized in Table I. All of these cell lines require 
tyrosine-specific kinase activity for proliferation. Inhi- 
bition of tyrosine-specific kinase activity could be a 
mechanism by which A77 1726 could inhibit cell 
growth. To investigate this possibility, an EGF-depend- 
ent human foreskin fibroblast cell line (HFF) was eval- 
uated for the ability of A77 1726 to inhibit EGF-stimu- 
lated proliferation. HFF cells were incubated in the 
presence or absence of different concentrations of A77 
1726 and after 4 days proliferation was measured by 
[3H]thymidine incorporation. The concentration f A77 
1726 required to inhibit 50% proliferation of HFF cells 
was approximately 30/zM (Fig. 2). Cell viability, as 
O 
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Fig. 1. The chemical structure of A77 1726. 
determined by Trypan blue exlusion, was unaffected at 
any of the drug concentrations u ed. The effect of A77 
1726 on HFF cell growth was also reversable: 48 h after 
removal of A77 1726, EGF stimulated HFF cell growth 
and proliferation similar to control cultures (data not 
shown). 
3.2. Inhibition of EGF receptor autophosphorylation by 
A77 1726 
Since A77 1726 appeared to inhibit EGF dependent 
cell growth, the effect of A77 1726 on the EGF receptor 
tyrosine-specific protein kinase activity was investi- 
gated. The results described in Fig. 3 indicate that A77 
1726 can inhibit the autophosphorylation of the EGF 
receptor in intact cells. Stimulation of HFF cells for 10 
min with EGF results in phosphorylation f a 170 kDa 
protein consistant with autophosphorylation f the 
EGF receptor (Fig. 3, Lanes 3 and 4). The identity of 
this band as the EGF receptor was confirmed by anti- 
EGF receptor monoclonal antibody (clone F4, Sigma) 
staining (data not shown). Human foreskin fibroblast 
cells incubated in the presence of 30/.tM A77 1726 and 
stimulated with EGF demonstrated reduced auto-phos- 
phorylation of the EGF receptor (Fig. 3, lanes 7 and 8). 
Cells grown in different concentrations of A77 1726 
revealed that the effective dose for inhibition of auto- 
phosphorylation (20-30 ktM, Fig. 4) was similar to the 
dose required for inhibition of cell growth (30 ¢tM, Fig. 
2). 
3.3. Inhibition of tyrosine kinase activity by A77 1726 
The ability of A77 1726 to directly inhibit the EGF 
receptor tyrosine-specific kinase was measured on puri- 
fied EGF receptors. Fig. 5 shows the inhibition of tyro- 
sine-specific kinase activity observed with increasing 
Table I 
Inhibition of cell proliferation by A77 1726 
Cell line Origin Species ED5o CuM) 
CTLL Cytotoxic T-cell Murine 40" 
(IL-2 dep.) 
A20-2-J BALB/c B-cell tumor Murine 3 
T-cells and B-cells Spleen Murine 10 
KB Epidermoid tumor Human 15 
A431 Epidermoid tumor Human 35 
7D4 B-cell hybridoma Rat 1 
aDetermined by [3H]thymidine incorporation. 
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Fig. 2. Inhibition of [3H]thymidine incorporation i to human foreskin 
fibroblast cells by A77 1726. 
concentrations of A77 1726. The inhibition curve was 
very similar to that seen for autophosphorylation n 
intact cells and inhibition of cell growth (IC50 3040 
pM). These results demonstrated that A77 1726 inhib- 
ited the tyrosine-specific protein kinase activity of the 
EGF receptor. Moreover, these results suggested that 
the ability of A77 1726 to inhibit EGF-dependent cell 
growth may be related directly to its ability to inhibit 
the tyrosine kinase activity of the EGF receptor. 
3.4. Specificity of A77 1726 inhibition 
The data described above indicated that A77 1726 
could inhibit the EGF receptor tyrosine kinase activity. 
The growth inhibition of the IL-2-dependent cytotoxic 
T-cell line (CTLL) suggested that A77 1726 may also be 
able to inhibit the kinase activity of the lyphocyte-spe- 
cific src family kinase (p56 l~k) (Table I) [15]. Additional 
data from the laboratory has indicated that A77 1726 
can reduce IL-2-dependent tyroslne phosphorylation in 
these cells (D. Nikcevich and E. Bremer, unpublished 
observation). Platelet-derived growth factor-dependent 
tyrosine phosphorylation was also inhibited by A77 
1726 in intact cells at concentrations similar to EGF- 
dependent phosphorylation described in Fig. 3 (data 
not shown). 
These data suggested that A77 1726 can inhibit a 
variety of tyrosine-specific kinases. We also tested the 
ability of A77 1726 to inhibit a serine/theonine-specific 
kinase. Protein kinase C (PKC) was chosen as a model 
A771726 + + + + 
EGF + + + + 
<-- 170 kd 
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Fig. 3. Inhibition of EGF receptor autophosphorylation by 30 ¢tM 
A77 1726. 
Table ii 
Inhibition of protein kinase C activity by A77 1726 
[A77 1726] (ttM) PKC activity a(pmol/min/106 cells) 
0 14.2 
25 13.4 
50 14.5 
100 15.0 
150 13.8 
~PKC activity was determined with PKC purified from the human 
myologenous leukemia cell line, HL-60, Enzyme activity was meas- 
ured by the transfer of 32P to a synthetic peptide substrate from ATP 
using the Gibco-BRL PKC assay kit as described in section 2. 
serine/theonine-specific kinase since it can phospho- 
rylate the EGF receptor and reduce the receptor's ki- 
nase activity [16]. A77 1726 was unable to inhibit PKC 
activity at concentrations ranging between 25 and 150 
/2M (Table II). At these concentrations, A77 1726 is able 
to strongly inhibit the EGF receptor kinase in both 
intact cells (Fig. 3) and in vitro (Fig. 5). These data 
indicate that A77 1726 is acting by directly inhibiting 
the tyrosine-specific kinase activity. 
4. DISCUSSION 
The data presented here demonstrates that A77 1726, 
the active metabolite of leflunomide, is able to inhibit 
EGF-dependent cell growth. This drug was also able to 
inhibit EGF receptor autophosphorylation n intact 
HFF cells. The concentration f drug required to inhibit 
autophosphorylation (20-30 ¢tM) was approximately 
the same concentration required to inhibit HFF prolif- 
eration (30M0/2M). The effect of A77 1726 on the EGF 
receptor autophosphorylation wasdue to a decrease in 
kinase activity (Fig. 5). The concentration (approx. 40 
¢tM) required for inhibition of the EGF receptor tyro- 
sine-specific kinase activity was the same as that re- 
quired for inhibition of cell growth, suggesting that inhi- 
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Fig, 4. Percent inhibition of EGF receptor autophosphorylation by 
various concentrations f A77 1726. 
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Fig. 5. Inhibition of the purified EGF receptor tyrosine-specific kinase 
activity by A77 1726. 
bition of  kinase activity may be the mechanism for 
growth inhibition by A77 1726. 
A variety of  compounds have been described as in- 
hibitors of  the EGF  receptor tyrosine-specific kinase 
activity. In cell-free kinase assays, many of  these com- 
pounds appear to be better inhibitors than A77 1726. 
Erbstatin has a Ki of  6.0 pM [12], genistein an ICs0 of 
2.6/2M for autophosphorylat ion f  the EGF  receptor 
[3], Tyrophostin RG50864 a K~ of  0.85 pM [5] and 
thiazoldine-diones an ICs0 of  1-6/2M [13]. On the other 
hand, some of  these kinase inhibitors are not nearly as 
effective in intact cells. Erbstatin and its analogs require 
greater than 130 pM concentrations to inhibit EGF  
receptor autophosphorylat ion in cultured A431 cells [4]. 
In this report, we describe cell growth inhibition by A77 
1726 at 35 pM for A431 cells and 30pM for HFF  cells. 
Furthermore, EGF  receptor autophosphorylat ion is in- 
hibited by A77 1726 at 30pM in intact cells. These data 
suggest hat A77 1726 is a very effective inhibitor of  the 
EGF  receptor kinase in live cells. 
Leflunomide was developed for its potential as an 
immunomodulatory drug and has been extensively 
studied in animal models [7,8]. The animal studies have 
indicated that leflunomide can inhibit graft rejection 
and adjuvant arthritis [7,8]. The ability of  A77 1726 to 
inhibit the EGF  receptor kinase suggests that the immu- 
nomodulat ion seen with this drug may be due to inhibi- 
tion of  tyrosine-specific protein kinase activities. Tyro- 
sine kinase activity has been implicated in the signal 
transduction mechanisms of  the T-cell receptor [t 7] and 
several cytokine receptors, including the IL-2 receptor 
[18]. In addition to leflunomide's potential as an immu- 
nomodulatory drug, the data presented there suggest 
that A77 1726 may be a useful tool for defining the role 
of  tyrosine-specific kinases in the activation of  T and B 
cells. 
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